It has been noted that Wnt3a can impact the progression of prostate cancer by enhancing the expression of cytosolic and nuclear β-catenin in addition to enhancing androgen receptor activity or inducing activity in absence of the androgen hormone [45, 46]. Here, WNT3A is linked to prostate carcinoma.